| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
225,410,000 |
| Market
Cap: |
181.68(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.4783 - $1.82 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 8 |
| Insider 3/6 Months : 8.6 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Co.'s clinical-stage product candidates include: Seralutinib, also known as GB002, which is an inhaled small molecule, platelet-derived growth factor receptor colony-stimulating factor 1 receptor and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, which is an oral small molecule for the treatment of inflammatory bowel disease; and GB5121, which an oral small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
232,000 |
232,000 |
1,400,505 |
| Total Buy Value |
$0 |
$138,093 |
$138,093 |
$2,465,139 |
| Total People Bought |
0 |
2 |
2 |
5 |
| Total Buy Transactions |
0 |
2 |
2 |
12 |
| Total Shares Sold |
44,068 |
44,068 |
45,882 |
93,276 |
| Total Sell Value |
$52,319 |
$52,319 |
$54,659 |
$345,585 |
| Total People Sold |
5 |
5 |
5 |
6 |
| Total Sell Transactions |
5 |
5 |
6 |
15 |
| End Date |
2024-01-18 |
2023-10-17 |
2023-04-18 |
2022-04-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Christian Waage |
EVP, Tech Ops and Admin |
• – – |
2024-03-27 |
4 |
S |
$1.16 |
$7,430 |
D/D |
(6,430) |
585,934 |
|
30% |
|
| Giraudo Bryan |
COO/CFO |
• – – |
2024-03-27 |
4 |
S |
$1.16 |
$7,431 |
D/D |
(6,430) |
92,737 |
|
30% |
|
| Hasnain Faheem |
President & CEO |
• • – |
2024-03-27 |
4 |
S |
$1.16 |
$26,773 |
D/D |
(23,172) |
120,293 |
|
30% |
|
| Aranda Richard |
Chief Medical Officer |
• – – |
2024-03-18 |
4 |
S |
$1.33 |
$5,342 |
D/D |
(4,018) |
198,799 |
|
41% |
|
| Peterson Caryn |
EVP, Regulatory Affairs |
• – – |
2024-03-18 |
4 |
S |
$1.33 |
$5,343 |
D/D |
(4,018) |
49,833 |
|
41% |
|
| Milligan Sandra |
Director |
– • – |
2023-11-15 |
4 |
B |
$0.79 |
$25,213 |
I/I |
32,000 |
32,000 |
2.1 |
44% |
|
| Giraudo Bryan |
COO/CFO |
• – – |
2023-11-13 |
4 |
B |
$0.56 |
$112,880 |
I/I |
200,000 |
380,010 |
1.99 |
108% |
|
| Giraudo Bryan |
COO/CFO |
• – – |
2023-07-24 |
4 |
A |
$1.82 |
$98,316 |
I/I |
54,020 |
180,010 |
|
- |
|
| Christian Waage |
EVP, Tech Ops and Admin |
• – – |
2023-07-24 |
4 |
A |
$1.82 |
$24,577 |
I/I |
13,504 |
45,892 |
|
- |
|
| Hasnain Faheem |
President & CEO |
• • – |
2023-07-24 |
4 |
A |
$1.82 |
$983,120 |
I/I |
540,176 |
5,036,073 |
|
- |
|
| Aranda Richard |
Chief Medical Officer |
• – – |
2023-06-22 |
4 |
S |
$1.29 |
$2,340 |
D/D |
(1,814) |
197,574 |
|
63% |
|
| Giraudo Bryan |
COO/CFO |
• – – |
2023-04-04 |
4 |
B |
$1.02 |
$56,095 |
I/I |
55,000 |
125,990 |
1.99 |
15% |
|
| Hasnain Faheem |
President & CEO |
• • – |
2023-03-22 |
4 |
B |
$1.14 |
$503,580 |
I/I |
440,500 |
4,495,897 |
2.66 |
25% |
|
| Hasnain Faheem |
President & CEO |
• • – |
2023-03-21 |
4 |
B |
$1.20 |
$322,324 |
I/I |
269,389 |
4,055,397 |
2.66 |
13% |
|
| Giraudo Bryan |
COO/CFO |
• – – |
2023-03-20 |
4 |
B |
$0.97 |
$48,435 |
I/I |
50,000 |
70,990 |
1.99 |
6% |
|
| Hasnain Faheem |
President & CEO |
• • – |
2023-03-20 |
4 |
B |
$1.03 |
$174,486 |
I/I |
168,683 |
3,786,008 |
2.66 |
6% |
|
| Christian Waage |
EVP, Tech Ops and Admin |
• – – |
2023-03-20 |
4 |
B |
$1.20 |
$22,145 |
I/I |
18,500 |
32,388 |
1.99 |
6% |
|
| Peterson Caryn |
EVP, Regulatory Affairs |
• – – |
2023-03-16 |
4 |
S |
$1.10 |
$8,305 |
D/D |
(7,564) |
53,851 |
|
-20% |
|
| Carter Laura |
Chief Scientific Officer |
• – – |
2023-03-16 |
4 |
S |
$1.10 |
$6,620 |
D/D |
(6,029) |
76,263 |
|
-20% |
|
| Aranda Richard |
Chief Medical Officer |
• – – |
2023-03-16 |
4 |
S |
$1.10 |
$8,304 |
D/D |
(7,563) |
199,388 |
|
-20% |
|
| Peterson Caryn |
EVP, Regulatory Affairs |
• – – |
2022-10-24 |
4 |
S |
$12.07 |
$57,431 |
D/D |
(4,757) |
61,415 |
|
88% |
|
| Aranda Richard |
Chief Medical Officer |
• – – |
2022-10-24 |
4 |
S |
$12.07 |
$57,431 |
D/D |
(4,757) |
205,430 |
|
88% |
|
| Carter Laura |
Chief Scientific Officer |
• – – |
2022-10-24 |
4 |
S |
$12.07 |
$58,868 |
D/D |
(4,876) |
82,292 |
|
88% |
|
| Christian Waage |
EVP, Tech Ops and Admin |
• – – |
2022-07-15 |
4 |
B |
$7.21 |
$49,994 |
I/I |
6,934 |
13,888 |
1.99 |
-19% |
|
| Giraudo Bryan |
COO/CFO |
• – – |
2022-07-15 |
4 |
B |
$7.21 |
$99,995 |
I/I |
13,869 |
20,990 |
1.99 |
-19% |
|
91 Records found
|
|
Page 1 of 4 |
|
|
0.01 (1.8%) 
